AwesomeCapital
Search This Blog
Monday, September 23, 2024
Ventyx $27 Million Strategic Investment from Sanofi
Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232
https://www.globenewswire.com/news-release/2024/09/23/2951350/0/en/Ventyx-Biosciences-Announces-27-Million-Strategic-Investment-from-Sanofi.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.